CoChat

Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma

Open access
Ilhan-Mutlu, Aysegül, Osswald, Matthias, Liao, Yunxiang, Gömmel, Miriam, Reck, Martin, Miles, David, Mariani, Paola, Gianni, Luca, Lutiger, Beatrix, Nendel, Viktor, Srock, Stefanie, Perez-Moreno, Pablo, Thorsen, Frits, von Baumgarten, Louisa, Preusser, Matthias, Wick, Wolfgang, Winkler, Frank · 2016 · Molecular Cancer Therapeutics

Published version of a preprint

The DOI matches its Crossref record; 36 of the 38 references it cites were found in a registry or an index.

Abstract

Patients with nonsquamous non–small cell lung cancer (nsNSCLC; largely lung adenocarcinoma) are at high risk of developing brain metastases. Preclinical data suggested that anti–VEGF-A therapy may prevent the formation of nsNSCLC brain metastases. Whether non-brain metastases are also prevented, and whether bevacizumab shows a brain metastases–preventive activity in cancer patients is unknown. Data of one nsNSCLC (stage IIIB/IV, AVAiL) and two breast cancer bevacizumab trials (HER2 negative, AVADO; HER2 positive, AVEREL) were retrospectively analyzed regarding the frequency of the brain versus other organs being the site of first relapse. For animal studies, the outgrowth of PC14-PE6 lung adenocarcinoma cells to brain macrometastases in mice was measured by intravital imaging: under control IgG (25 mg/kg) treatment, or varying doses of bevacizumab (25 mg/kg, 2.5 mg/kg, 0.25 mg/kg). Brain metastases as site of first relapse were significantly less frequent in the bevacizumab arm of the AVAiL trial (HR = 0.36, P < 0.001). In AVADO and AVEREL, no significant difference was seen. In mice, bevacizumab treatment led to secondary regressions of non-brain macrometastases, but did not reduce their total incidence, and did not improve survival. In a brain-seeking nsNSCLC metastasis model, treatment with bevacizumab inhibited brain metastases formation, which resulted in improved overall survival. In summary, bevacizumab has the potential to prevent brain metastases in nsNSCLC, but no preventive activity could be detected outside the brain. These data indicate that anti–VEGF-A agents might be particularly relevant for those stage III nsNSCLC patients who are at high risk to develop future brain metastases. Mol Cancer Ther; 15(4); 702–10. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-15-0582

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 123

Metadata

Authors
Ilhan-Mutlu, A., Osswald, M., Liao, Y., Gömmel, M., Reck, M., Miles, D., Mariani, P., Gianni, L., Lutiger, B., Nendel, V., Srock, S., Perez-Moreno, P., Thorsen, F., von Baumgarten, L., Preusser, M., Wick, W., & Winkler, F.
Affiliations
  • 1Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • German Cancer Research Center (DE)
  • German Center for Lung Research (DE)
  • Mount Vernon Cancer Centre (GB)
  • Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
  • IRCCS Ospedale San Raffaele (IT)
  • F. Hoffmann-La Roche AG (CH)
  • 10DASTA GmbH, Heddesheim, Germany.
  • University of Bergen (NO)
  • 12Department of Neurology, Ludwig-Maximilians University Hospital, Munich, Germany.
  • Comprehensive Cancer Center Vienna (AT)
Corresponding author
Winkler, Frank
Venue
Molecular Cancer Therapeutics
Published
2016-04-01
Volume
15
Issue
4
Pages
702-710
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2302258098
Cited by
119
References
38
Citations by year
2026: 2 · 2025: 6 · 2024: 9 · 2023: 9 · 2022: 9 · 2021: 14 · 2020: 19 · 2019: 19 · 2018: 18 · 2017: 6 · 2016: 8
FWCI
15.19
Type
journal article
Language
en
Open access
Locations
  • Molecular Cancer Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Brain Metastases and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
bevacizumab, brain metastases, lung adenocarcinoma, non-small cell lung cancer, metastasis prevention, intravital imaging, breast cancer, overall survival
MeSH terms
Bevacizumab, Adenocarcinoma of Lung, Adenocarcinoma, Animals, Antineoplastic Agents, Brain Neoplasms, Disease Models, Animal, Humans, Lung Neoplasms, Neoplasm Recurrence, Local, Neoplasm Staging, Neovascularization, Pathologic, Retrospective Studies, Multicenter Studies as Topic, Incidence, Randomized Controlled Trials as Topic, Clinical Trials, Phase III as Topic, Angiogenesis Inhibitors, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma. https://app.cochat.ai/papers/10.1158/1535-7163.mct-15-0582
The paper
Ilhan-Mutlu, A., Osswald, M., Liao, Y., Gömmel, M., Reck, M., Miles, D., Mariani, P., Gianni, L., Lutiger, B., Nendel, V., Srock, S., Perez-Moreno, P., Thorsen, F., von Baumgarten, L., Preusser, M., Wick, W., & Winkler, F. (2016). Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-15-0582

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.